Developing monoclonal antibodies to treat dangerous viral infections.
Core B - MappBiopharmaceutical, Inc.
This study is working on developing special antibodies to help fight against the Hendra and Nipah viruses, which can make people very sick, with the goal of creating safe and effective treatments to protect and treat those affected by these viruses.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry M. Jackson Fdn for the Adv Mil/med NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project ID | NIH-10581494 on NIH RePORTER |
What this research studies
This research focuses on creating monoclonal antibodies (mAbs) to combat two highly dangerous viruses, Hendra virus (HeV) and Nipah virus (NiV), which can cause severe respiratory and neurological diseases in humans. The approach involves leveraging the established safety and efficacy of mAbs, which have been successfully used in treating various infectious diseases. The research aims to develop effective antiviral therapies that can be used for prevention and treatment of infections caused by these viruses, addressing a critical public health need.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals at risk of exposure to Hendra and Nipah viruses, particularly those in endemic regions.
Not a fit: Patients with infections caused by other viruses not targeted by this research may not receive any benefit.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments for infections caused by Hendra and Nipah viruses, potentially saving lives.
How similar studies have performed: Previous research has shown success in developing monoclonal antibodies for other viral infections, indicating a promising potential for this approach.
Where this research is happening
Bethesda, United States
- Henry M. Jackson Fdn for the Adv Mil/med — Bethesda, United States (Active)
Researchers
- Principal investigator: Zeitlin, Larry — Henry M. Jackson Fdn for the Adv Mil/med
- Study coordinator: Zeitlin, Larry
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.